Coherus BioSciences Inc expected to post a loss of 29 cents a share - Earnings Preview

Coherus Oncology

07/08/2024 03:04

* Coherus BioSciences Inc  CHRS.OQ   CHRS.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 8
for the period ending June 30 2024
    * The Redwood City California-based  company is expected to
report
a 4.5% increase in revenue to $61.366 million from $58.72
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Coherus BioSciences Inc
is for
a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Coherus
BioSciences Inc is $8.00​, above​ its last closing price
of $1.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.25       -0.24      -0.32     Missed  -32.3
 Dec. 31 2024  -0.14       -0.12      -0.62     Missed  -420.3
 Sep. 30 2023  -0.29       -0.27      -0.27     Met     1.7​
 Jun. 30 2023  -0.48       -0.48      -0.38     Beat    21.6
 ​​Mar.        -0.54       -0.57      -0.75     Missed  -31
 31 2023                                                
 Dec. 31 2022  -0.87       -0.84      -0.60     Beat    28.4​
 Sep. 30 2022  -0.56       -0.57      -0.96     Missed  -68.4
 Jun. 30 2022  -0.64       -0.64      -0.47     Beat    26.6
 This summary was machine generated August 7 at 02:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)